Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Dyadic International Inc., DE

Moderna

Pfizer

The process of lining up the next wave of vaccines – Vax 2.0 – is likely already underway behind closed doors at major science institutes, throughout top research think-tanks, and at the home bases of the major vaccine-oriented pharma players. Vax 2.0 is no longer a theory.

Leading Vaccine Stocks Under the Microscope (PFE, NVAX, DYAI, MRNA)

NVAX delayed plans for regulatory approval of its COVID-19 vaccine, disappointing the market. NVAX CEO Stan Erck recently indicated the company is in good shape pursuant to its approval filing.

Novavax CEO Claims The Company Is 'In Good Shape' For Approval Filing

Overseas Covid-19 vaccine deals could save the day, but it's hard to imagine the dwindling prospects of NVAX stock turning on a dime. The post With a Stumbling Track Record, All Signs Say Stay Away from Novavax appeared first on InvestorPlace.

With a Stumbling Track Record, All Signs Say Stay Away from Novavax

Moderna and Pfizer got their COVID-19 vaccines to market fast. Will there be any opportunity left for Novavax to win market share?

Has Novavax Lost the Vaccine Race to Moderna?

Broadcom

Skillz

Dogecoin has the look of a pump-and-dump scheme. That's why successful money managers are buying these stocks instead.

Dump Dogecoin: Smart Investors Are Buying These Supercharged Stocks

Once a very promising play on the Covid-19 pandemic, Novavax has lost serious momentum, putting NVAX stock under question. The post Once-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran appeared first on InvestorPlace.

Once-Bright Light Novavax Stares Into a Dimming Future as Vaccine Also-Ran

GAITHERSBURG, Md., May 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M.

Novavax to Present at International Society for Vaccines Virtual Congress COVID-19 Vaccine Update

The U.S. now supports waiving patent rights at the World Trade Organization for COVID-19 vaccines. How bad is this news?

Will the COVID Vaccine Companies Fall off the Patent Cliff?

Canada's vaccination rate is about to pass the U.S. That does not bode well for Novavax and NVAX stock. Are children the company's savior?

Are Children the Solution to Novavax's Vaccine Problem?

Novavax Inc (NASDAQ: NVAX) reaffirmed its partnership with South Korean firm SK Bioscience Co Ltd to expand its production of vaccines, including Novavax's protein-based COVID-19 vaccine candidate NVX-CoV2373. In February, Novavax had entered into a license agreement with the South Korean manufacturer to produce 40 million doses of the COVID-19 vaccine for the country.

Novavax Expands COVID-19 Vaccine Pact In South Korea

It could even be the most likely to succeed.

The Top Reason Novavax Could Still Be a Huge Winner in the COVID-19 Vaccine Market

GAITHERSBURG, Md., May 22, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the signing of a non-binding memorandum of understanding (MoU) with the Ministry of Health and Welfare of Korea (MOHW) and SK bioscience, Co. Limited, a vaccine business subsidiary of SK Group, to explore further cooperation in the development and manufacturing of vaccines, including NVX-CoV2373, Novavax' recombinant protein COVID-19 vaccine candidate.

Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea

GAITHERSBURG, Md., May 21, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that the Maryland Tech Council's (MTC's) nominating committee chose Novavax as the recipient of its 'Life Sciences Company of the Year' award and chose Stanley C.

Novavax Honored by Maryland Tech Council During 2021 Industry Awards Celebration

Bumble

Castor Maritime Inc

Hertz

Marathon Digital Holdings

SNDL Inc.

While the market is still in the euphoria phase, it's the appropriate time to consider stocks to sell just in case the worst happens. The post 7 Stocks to Sell Now While You Still Have the Chance appeared first on InvestorPlace.

7 Stocks to Sell Now While You Still Have the Chance

After enjoying a stunning resurgence as an unlikely COVID-19 vaccine leader, Novavax is now staring down its biggest challenge yet: can it finish what it started? The Maryland biotech company has said it will announce results from a pivotal US clinical trial of the experimental shot by the end of next month. Weirdly enough, what that study will show isn't the main question surrounding Novavax.

Novavax could have the 'best' COVID-19 shot, but new delays are raising questions about the $10 billion biotech's path to profits

Last year's massive gain was only the beginning of the story.

Here's Why This Top Stock Is a Buy on the Dip

NVAX stock is in danger of repeating prior failures. The window of opportunity is closing and it's a movie investors have seen before.

Novavax Window of Opportunity Is Closing Fast

Bionano Genomics

Plug Power

Riot Blockchain

Are these popular momentum stocks too cheap to ignore or blatant value traps?

5 Risky Stocks With 138% to 216% Upside, According to Wall Street

The shares of Novavax, Inc. (NASDAQ: NVAX) have received a price target decrease from $317 to $294 by H.C. Wainwright.

Novavax (NVAX) Stock: $294 Target By H.C. Wainwright

GameStop

With gains ranging from 450% to nearly 3,000%, these big companies have been unstoppable.

4 Large-Cap Stocks That Turned $200,000 Into $1 Million (or More) in 1 Year

With strong liquidity and a massive vaccine market, Novavax is perfectly positioned in the industry. NVAX stock is a good buy in the dip.

The Dip In Novavax Is The Perfect Buying Opportunity

If Novavax is successful, it could generate billions.

This Is Novavax's Biggest Weakness Right Now -- and Here's How the Company May Overcome It

Human trials of the combination vaccine are expected to start later this year.

Novavax Reports Positive Data From Animal Trial of Its COVID-19/Flu Combo Shot

Novavax, Inc. (NASDAQ:NVAX) shares are trading lower by 3.7% at $133.05 after JPMorgan downgraded the stock from Overweight to Neutral and lowered its price target from $285 to $161 per share. Novavax is a biotechnology company that develops vaccines.

Why Novavax Is Moving Today

The stock price of Novavax has seen a large 18% drop in just five trading sessions. The decline was driven partly due to the company's announcement that it doesn't plan to file for authorization for its Covid-19 vaccine in the U.S. and Europe until Q3 of this year.

News for Novavax Stock (NVAX)